MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CCT241736

CAS No. : 1402709-93-6

MCE 站：CCT241736

产品活性：CCT241736 是一种有效的，可口服的 FLT3 和 Aurora kinase 双重抑制剂，能够有效抑制 Aurora-A (K_d，7.5 nM；IC₅₀，38 nM)，Aurora-B (K_d，48 nM)，FLT3 (K_d，6.2 nM)，以及 FLT3 突变体 FLT3-ITD (K_d，38 nM) 和 FLT3(D835Y) (K_d，14 nM) 的活性。

研究领域：Protein Tyrosine Kinase/RTK  |  Epigenetics  |  Cell Cycle/DNA Damage

作用靶点：FLT3  |  Aurora Kinase

In Vitro: CCT241736 (Compound 27e) is a potent ａnd orally bioavailable dual FLT3 ａnd Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC₅₀, 38 nM, Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), ａnd FLT3 mutants including FLT3-ITD (K_d, 38 nM) ａnd FLT3(D835Y) (K_d, 14 nM). CCT241736 exhibits antiproliferative activity in a range of human tumor cell lines, such as HCT116 human colon carcinoma (GI₅₀, 0.300 μM), the human FLT3-ITD positive AML cell lines MOLM-13 (GI₅₀, 0.104 μM) ａnd MV4-11 (GI₅₀, 0.291 μM). CCT241736 also inhibits both the autophosphorylation of Aurora-A at T288 (a biomarker for Aurora-A inhibition: IC₅₀, 0.030 μM) ａnd histone H3 phosphorylation at S10 (a biomarker for Aurora-B inhibition: IC₅₀, 0.148 μM), consistent with potent cellular activity versus both Aurora-A ａnd -B. CCT241736 suppresses Aurora-A in MOLM-13 cells with concomitant inhibition of FLT3 signaling.

In Vivo: CCT241736 (50, 100 mg/kg, b.i.d, p.o.) dose-dependently suppresses the growth of MV4-11 human tumor xenografts, ａnd completely abolishes the tumors at 100 mg/kg via p.o. administration twice a day.

相关产品：Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Membrane Protein-targeted Compound Library  |  Cytokine Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  AAPK-25  |  JNJ-47117096 hydrochloride  |  Sorafenib-d₄  |  AT9283  |  (E/Z)-Zotiraciclib  |  AKN-028 acetate  |  Aurora kinase inhibitor-3  |  Aurora Kinases-IN-2  |  Sorafenib Tosylate  |  BPR1K871  |  ENMD-2076 Tartrate  |  Barasertib-HQPA  |  AZD2932  |  dAURK-4  |  AMG 900  |  SCH-1473759  |  Aurora A inhibitor 1  |  BI-847325  |  Hypothemycin  |  UNC2025 hydrochloride  |  Tandutinib  |  CCT129202  |  UNC4203  |  Tripolin A  |  3-Hydroxy Midostaurin  |  Cabozantinib  |  ZM-447439  |  LBW242  |  LY3295668

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。